Factors predicting survival during replacement therapy for end stage renal disease

被引:0
作者
Corte, CD
Ortega, F
Rebollo, P
Baltar, JM
Alvarez, R
Alvarez-Ude, F
Badía, X
Fernández, E
Rodríguez, M
Grande, JA
机构
[1] Hosp Cent Asturias, Serv Nefrol, Oviedo 33006, Spain
[2] Inst Salut Publ Catalunya, Barcelona, Spain
来源
NEFROLOGIA | 1999年 / 19卷 / 03期
关键词
end stage renal disease; replacement therapy; survival;
D O I
暂无
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: The number of patients who are started on RRT is constantly increasing, thus, it is essential to know what life expectancy is being offered, and what factors predict survival. Material and methods: Retrospective study of a sample including over 80% of the patients (468) who were started on RRT in our region between 1985 and 1994, in order to find factors predicting survival, analysing global and univariate (Kaplan-Meier) survival, as well as relative death risks using Cox multivariate method. Results and conclusions: In our sample, global survival at 12, 24, 60 and 96 months was 90% 82%, 61% and 50%, respectively. Mean survival time was 80 months, with 95% confidence limits (Cl 95) of 75 and 85 months. When comparing survival curves, differences significant were observed for the following: age, main, diagnosis functional status, previous renal transplant, haemoglobin level, serum creatinine bevel and comorbidity index. Univariate analysis did not show significant differences in survival time of RRT patients with respect to: year of starting therapy, sex, marital status, haematocrit or serum urea level. When the multivariate model was applied, it was observed that death risk was reduced by variable "having received a transplant" (RR = 0.89; CI 95: 0.85-0.94). Death risk was increased by variables "main diagnosis = diabetes" (RR = 2.26; CI 95: 1.35-3.79) and "functional status grades 1 and 2" (RR = 5.13; CI 95: 2.7-0.74 and RR = 1.46 CI 95: 0.98=2.17 respectively). The remaining variables identified by the univariate model were longer significantly associated with survival.
引用
收藏
页码:244 / 253
页数:10
相关论文
共 47 条
[1]   End-stage renal disease in the USA: Data from the United States renal data system [J].
Agodoa, LY ;
Jones, CA ;
Held, PJ .
AMERICAN JOURNAL OF NEPHROLOGY, 1996, 16 (01) :7-16
[2]  
AlvarezUde F, 1995, NEFROLOGIA, V15, P572
[3]   Patient survival after renal transplantation; more than 25 years follow-up [J].
Arend, SM ;
Mallat, MJK ;
Westendorp, RJW ;
vanderwoude, FJ ;
vanEs, LA .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1997, 12 (08) :1672-1679
[4]  
AVARAM MM, 1995, AM J KIDNEY DIS, V26, P209
[5]   Enrollment parathyroid hormone level is a new marker of survival in hemodialysis and peritoneal dialysis therapy for uremia [J].
Avram, MM ;
Sreedhara, R ;
Avram, DK ;
Muchnick, RA ;
Fein, P .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1996, 28 (06) :924-930
[6]   Predictive value of nutritional markers (albumin, creatinine, cholesterol, and hematocrit) for patients on dialysis for up to 30 years [J].
Avram, MM ;
Bonomini, LV ;
Sreedhara, R ;
Mittman, N .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1996, 28 (06) :910-917
[7]  
BALTAR J, 1997, NEFROLOGIA S2, V17, pA119
[8]  
Barrio V, 1997, NEFROLOGIA, V17, P365
[9]   Relationship of dose of hemodialysis and cause-specific mortality [J].
Bloembergen, WE ;
Stannard, DC ;
Port, FK ;
Wolfe, RA ;
Pugh, JA ;
Jones, CA ;
Greer, JW ;
Golper, TA ;
Held, PJ .
KIDNEY INTERNATIONAL, 1996, 50 (02) :557-565
[10]  
Burdick CO, 1998, AM J KIDNEY DIS, V31, P195